Table 1 Demographic and clinical characteristics of randomized subjects at baseline
From: Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease
|
IVIG n = 24 (49.0%) |
Placebo n = 25 (51.0%) | |||
|---|---|---|---|---|
| n (%) | Mean ± SD | n (%) | Mean ± SD | |
| Age | 72.20 ± 7.91 | 72.34 ± 7.36 | ||
| Female | 14 (58.3) | 14 (56.0) | ||
| Education | ||||
| < 12 years | 0 | 0 | ||
| 12 years | 2 (9.5) | 3 (13.6) | ||
| > 12 to 16 years | 9 (42.9) | 11 (50.0) | ||
| > 16 years | 10 (47.6) | 8 (36.4) | ||
| BMI | 25.48 ± 5.44 | 26.96 ± 4.26 | ||
| Comorbids | ||||
| Asthma/COPD | 4 (16.7) | 2 (8.0) | ||
| Diabetes | 5 (20.8) | 5 (20.0) | ||
| Hypertension | 10 (41.7) | 8 (32.0) | ||
| Hyperlipidemia | 13 (54.2) | 10 (40.0) | ||
| CAD/PVD | 4 (16.7) | 6 (24.0) | ||
| APOE ε4 | 15 (62.5) | 14 (56.0) | ||
| Aβ42 < 482 pg/mLa | 16 (94.1) | 15 (88.2) | ||
| Aβ42 pg/mLa | 294.00 ± 96.55 | 353.41 ± 112.99 | ||
| tau pg/mLa | 107.47 ± 58.65 | 96.18 ± 65.47 | ||
| p-tau pg/mLa | 43.59 ± 19.90 | 39.47 ± 30.27 | ||
| Ventricular volume (cm3) | 53.64 ± 26.84 | 51.72 ± 22.28 | ||
| MMSE | 26.75 ± 2.15 | 26.44 ± 2.60 | ||
| ADAS-cog | 10.21 ± 4.38 | 10.28 ± 5.67 | ||
| CDR-SB | 1.96 ± 0.95 | 1.60 ± 0.90 | ||
| MCI Stage | ||||
| Early (CDR-SB ≤ 1.0) | 6 (25.0) | 13 (52.0) | ||
| Late (CDR-SB > 1.0) | 18 (75.0) | 12 (48.0) | ||